The survival and prognostic factors of head and neck cancer patients over the age of 80 in comparison to their younger counterparts: Cohort study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Advanced age is not a predictor of survival in head and neck squamous cell carcinoma patients over 80. Prognostic scores like the Performance Status (PS) and G8 are more reliable indicators for treatment outcomes.
Area Of Science
- Oncology
- Geriatric Medicine
- Head and Neck Surgery
Background
- Head and neck squamous cell carcinoma (HNSCC) is a significant cause of cancer-related mortality.
- Elderly patients (≥70 years) often present unique challenges in HNSCC management.
- The prognostic impact of advanced age (≥80 years) on HNSCC outcomes requires further clarification.
Purpose Of The Study
- To compare overall survival (OS) and prognostic factors in HNSCC patients aged ≥80 years versus those aged 70-79 years.
- To determine if advanced age is an independent prognostic factor for HNSCC.
- To identify reliable prognostic indicators for elderly HNSCC patients.
Main Methods
- Retrospective study of 346 HNSCC patients treated with curative intent between 2013 and 2021.
- Patients were stratified into two groups: Group 1 (≥80 years) and Group 2 (70-79 years).
- Overall survival (OS) and recurrence-free survival (RFS) were analyzed, along with prognostic factors including age, disease stage, and performance scores.
Main Results
- No significant difference in median OS (39 vs. 41 months) or RFS (33 vs. 34 months) was observed between the two age groups.
- Locally advanced disease and combined surgery/radiotherapy treatment were associated with poorer OS.
- Locally advanced stage was the sole predictor of RFS; age was not a significant prognostic factor.
- Performance Status (PS), ASA score, and G8 score demonstrated significant prognostic value.
Conclusions
- Advanced age (≥80 years) is not an independent risk factor for survival in HNSCC patients.
- Age alone should not preclude elderly patients from receiving optimal curative-intent treatment.
- Prognostic scores (PS, G8) are more reliable than age for predicting oncological outcomes in elderly HNSCC patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...